<DOC>
	<DOCNO>NCT01300260</DOCNO>
	<brief_summary>The purpose study measure effect LY2189265 increase insulin level response glucose intake .</brief_summary>
	<brief_title>Effect LY2189265 Insulin Secretion Response Intravenous Glucose</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>All Participants Women must surgically sterile ( hysterectomy bilateral oophorectomy tubal ligation ) postmenopausal define age &gt; 45 year without use oral contraceptive agent great 1 year either : spontaneous amenorrhea great 12 month , spontaneous amenorrhea 6 12 month document follicle stimulate hormone ( FSH ) &gt; 25 milli international units/milliliter ( mIU/mL ) serum estradiol &lt; 73 picomoles/liter ( pmol/L ) ( 20 picograms/milliliter [ pg/mL ] ) Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly ethical review board govern site Have serum creatinine &lt; 150 micromoles/liter ( µmol/L ) ( &lt; 1.3 milligrams/deciliter [ mg/dl ] woman , &lt; 170 µmol/L [ &lt; 1.5 mg/dL ] men ) Have normal hemoglobin result , determine investigator Healthy Participants Overtly healthy men woman determine medical history , normal lab result physical examination . Body mass index ( BMI ) 19 25 kilograms/meter square ( kg/m^2 ) , inclusive . Normal blood pressure heart rate determine investigator Have normal response oral glucose tolerance test ( OGTT ) ( glucose &lt; 7.8 millimoles/liter [ mmol/L ] [ &lt; 140 mg/dL ] 2 hour 75 gram ( g ) oral glucose load ) Participants type 2 diabetes mellitus ( T2DM ) Participants BMI 22.0 40.0 kg/m^2 Have T2DM control diet exercise alone metformin least 4 week prior admission Have hemoglobin A1c ( HbA1c ) value screening ( within 4 week prior screen ) 6.0 % 9.5 % Diagnosed T2DM within past 10 year Clinical laboratory test result within normal range deem clinically insignificant Investigator . Abnormalities serum glucose , serum lipid , urinary glucose , urinary protein consistent T2DM acceptable . Participants take stabledose prescription medication ( example , antihypertensive agent , aspirin , lipidlowering agent ) treatment concurrent medical condition permit participate provide medication associate development torsade de pointes . However , use betablockers thiazide diuretic permit study . All Participants Within 30 day initial dose study drug , receive treatment drug receive regulatory approval indication Known allergy GlucagonLike Peptide 1 ( GLP1 ) relate compound Have previously complete withdrawn study study last year investigate glucagonlike peptide incretin mimetics include exenatide ( Byetta® ) Regular use know drug abuse and/or positive finding urinary drug screening , finding consistent medication prescribe participant 's physician ( ) History presence cardiovascular , respiratory , renal , endocrine ( except T2DM ) , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug constitute risk take study medication interfere interpretation data Have history presence gastrointestinal disorder Poorly control hypertension ( systolic great 160 millimeter mercury [ mmHg ] , diastolic great 95 mmHg ) and/or evidence labile blood pressure include symptomatic postural hypotension . Use betablockers thiazide diuretic permit study Have clinically significant history cardiac disease presence active cardiac disease within 1 year screen period Evidence hepatitis C and/or positive hepatitis C antibody Evidence hepatitis B and/or positive hepatitis B surface antigen Evidence human immunodeficiency virus ( HIV ) and/or positive HIV antibody Have average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) unwilling follow alcohol restriction ( 1 unit = 12 ounce [ oz ] 360 milliliter [ mL ] beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Smoke 10 cigarette equivalent nicotine use nicotine substitute per day Regular use systemic corticosteroid oral , intravenous , intramuscular route , potent , inhale , intranasal steroid know high rate systemic absorption Have history presence significant active neuropsychiatric disease Blood donation 500 mL last 3 month blood donation within last month Any condition , opinion investigator would preclude participation study An abnormality 12lead electrocardiogram ( ECG ) opinion investigator increase risk participate study . Any clinically significant abnormal hematology , clinical chemistry , urinary result ( ) determine investigator Evidence significant active uncontrolled endocrine autoimmune abnormality ( example thyroid disease , pernicious anemia ) judge screen physician Healthy Participants Intended use overthecounter prescription medication 7 14 day , respectively , prior dosing . Participants T2DM Clinically significant peripheral vascular occlusive disease ( PVOD ) . Known severe exudative diabetic retinopathy Known significant autonomic neuropathy evidence urinary retention , diabetic diarrhea , gastroparesis Have experience ketoacidotic episode ( pH less 7.3 ) require hospitalization last 6 month Outpatient use insulin control diabetes within past 2 year Use antidiabetic agent metformin 4 week prior study entry use thiazolidinediones within 12 week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>